Lexaria Bioscience completes dosing for GLP-1 human pilot study #3

Lexaria Bioscience (LEXX) announced that dosing has been completed for human pilot study #3 investigating a DehydraTECH-processed version of the dual action glucagon-like peptide-1+ glucose-dependent insulinotropic peptide receptor agonist tirzepatide in an oral dose format. The Study has been dosed in nine healthy volunteers. The final seven-day dosing phase, wherein all subjects received the opposite treatment condition from that which they received during the initial dosing phase, was completed on November 16th. The initial dosing phase of either a seven-day regimen of oral DehydraTECH-processed tirzepatide capsules or a single injected tirzepatide dose was reported upon positively several weeks ago. No serious adverse events have been observed thus far during both dosing visits, which serves as a point of interest given Lexaria’s desire to create an effective oral version of Eli Lilly’s tirzepatide products, which currently only exist in an injectable form. The DehydraTECH composition for the Study was compound-formulated using the commercially available Zepbound injectable formulation as the tirzepatide input material. Tolerability, blood absorption levels, and blood sugar control are being evaluated in the Study. Through the Study, Lexaria is attempting to evidence meaningful absorption rates of tirzepatide in an oral format, which is not available in the market today since it is currently administered only by injection. The Company expects that data analysis will occur in December with results available in January, 2025.